Anagenics completes A$2.5 million haircare IP sale to York St Brands
Anagenics Limited (ASX: AN1) has completed an unconditional asset sale agreement with YSB IP Pty Ltd, part of York St Brands (YSB), covering its haircare technology and associated intellectual property, including the évolis brand assets (Sale IP). The sale of intellectual property delivers A$2.5 million (ex. GST) in cash on completion on 5 November 2026.
Anagenics also received A$0.16 million of quarter-to-date royalties under the prior licence arrangement. Cash arrives immediately, and sales-linked income continues through an earn-out over sales of YSB’s products that use the Sale IP.
The haircare technology was licensed to YSB in July 2024 for the creation of its Bouf brand. The sale crystallises the value of that licence and marks the next phase of the partnership.
When big ASX news breaks, our subscribers know first
Earn-out terms and what the numbers could deliver
The consideration payable for the Sale IP under the sale agreement comprises:
- An upfront payment of A$2.5 million, paid on completion.
- Quarterly payments equal to 4% of net sales of products utilising the Sale IP, for up to eight years, subject to an annual minimum payment to Anagenics of A$350,000.
- Future sales-linked payments capped at A$7 million in aggregate, in addition to the A$2.5 million completion payment.
- Early payout provisions in specified circumstances, using a discounted calculation of the remaining cap balance at an annual discount rate of 12.5%.
The approximately A$2.8 million in full-term minimum earn-out payments form part of, and are not additional to, the A$7 million cap.
Implied payments of over $6 million are based on recent sales values. Reaching the A$7 million cap, or achieving over A$6 million based on current run-rate, depends on future sales and the agreement terms and is not a guaranteed outcome.
| Component | Amount | Basis | Status |
|---|---|---|---|
| Licence fees | A$2.2M | Prior licence arrangement | To date |
| Completion payment | A$2.5M | Upfront payment under the sale agreement | Paid on completion, 5 November 2026 |
| Contractual minimum earn-out | c. A$2.8M | Minimum payments over eight-year term | Contractual minimum, part of the A$7M cap |
| Implied future earn-out | Over A$6M | Recent sales values and current run-rate | Depends on future sales |
If the current sales run-rate is maintained, Anagenics’ arrangements with YSB would deliver over A$10 million in aggregate value. That figure comprises A$2.2 million in licence fees to date, the A$2.5 million completion payment and over A$6 million in future earn-out payments.
How sales-linked IP deals work
An earn-out is a payment structure where the seller of an asset continues to receive money based on the asset’s future sales. Here, Anagenics receives quarterly payments tied to net sales of YSB products that use the Sale IP.
A minimum payment is the lowest amount owed each year regardless of sales, which is A$350,000 annually in this case. A cap is the maximum total that sales-linked payments can reach, set here at A$7 million in aggregate.
Building on Bouf’s success, the structure gives YSB the opportunity to unlock further value from the Sale IP through its sales and marketing expertise. Anagenics retains exposure to that growth through ongoing sales-linked payments without being directly responsible for funding commercialisation.
The trade-offs for a seller in this type of arrangement include:
- Certainty: the upfront payment and annual minimum provide contracted cash.
- Upside: payments above the minimum depend on future sales, up to the cap.
- Limit: the cap restricts total sales-linked payments to A$7 million.
Building on a maiden profit and a simpler portfolio
The sale follows Anagenics’ maiden full-year net profit after tax of A$308,472 for the year ended 30 June 2026, compared with an A$1.24 million loss in FY25. The company said the transaction builds on that turnaround.
It also crystallises value from the capital invested by shareholders and the work undertaken by Anagenics and its staff to develop the Sale IP over many years. The transaction strengthens the balance sheet and provides additional financial and strategic flexibility as Anagenics simplifies its portfolio.
Anagenics outlined its strategic priorities:
- Further improving the portfolio of brands operated by BLC Cosmetics, its wholly owned subsidiary focused on sales and distribution.
- Evaluating complementary growth opportunities.
- Disciplined capital allocation.
- Active discussions to monetise its non-haircare intellectual property.
For investors, the sale pairs A$2.5 million in immediate cash with continuing sales-linked income, following the first full-year profit in the company’s reporting history.
Get Healthcare and Biotech News Before the Market Moves
Get FREE breaking ASX news delivered to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ investors already using Big News Blast to stay ahead of the crowd. Click the “Free Alerts” button today and see market-moving announcements the moment they break.